First Hawaiian Bank Sells 34,606 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

First Hawaiian Bank lowered its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 22.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 122,015 shares of the biotechnology company’s stock after selling 34,606 shares during the period. First Hawaiian Bank owned about 0.05% of ADMA Biologics worth $805,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ADMA. Arizona State Retirement System lifted its stake in shares of ADMA Biologics by 4.9% in the 4th quarter. Arizona State Retirement System now owns 59,728 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 2,769 shares during the period. Swiss National Bank boosted its stake in shares of ADMA Biologics by 1.0% during the 3rd quarter. Swiss National Bank now owns 439,800 shares of the biotechnology company’s stock worth $1,574,000 after acquiring an additional 4,300 shares during the last quarter. Eagle Asset Management Inc. increased its stake in shares of ADMA Biologics by 20.2% in the 4th quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 4,367 shares in the last quarter. Victory Capital Management Inc. raised its holdings in ADMA Biologics by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 29,192 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 5,465 shares during the period. Finally, Raymond James & Associates lifted its position in ADMA Biologics by 2.3% during the fourth quarter. Raymond James & Associates now owns 249,296 shares of the biotechnology company’s stock valued at $1,127,000 after purchasing an additional 5,657 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Insider Buying and Selling

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the completion of the transaction, the chief executive officer now owns 2,081,475 shares in the company, valued at approximately $22,313,412. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.70% of the stock is owned by company insiders.

ADMA Biologics Trading Up 0.8 %

Shares of ADMA opened at $10.71 on Friday. The firm has a market cap of $2.48 billion, a P/E ratio of -535.50 and a beta of 0.48. The company has a debt-to-equity ratio of 0.91, a current ratio of 5.21 and a quick ratio of 1.86. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $10.99. The company has a 50 day simple moving average of $8.52 and a two-hundred day simple moving average of $6.38.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.03. The company had revenue of $81.90 million during the quarter, compared to analysts’ expectations of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. ADMA Biologics’s quarterly revenue was up 43.9% on a year-over-year basis. During the same period last year, the company posted ($0.03) earnings per share. On average, equities analysts expect that ADMA Biologics, Inc. will post 0.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on ADMA shares. Cantor Fitzgerald raised their price objective on ADMA Biologics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday, May 10th. HC Wainwright raised their target price on shares of ADMA Biologics from $7.50 to $10.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Mizuho lifted their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Thursday. Finally, Raymond James increased their price objective on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, ADMA Biologics presently has an average rating of “Buy” and a consensus target price of $11.00.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.